Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Depreciation & Amortization (CF) data on record, last reported at $8.1 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 11.22% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $31.6 million, down 13.03%, while the annual FY2025 figure was $31.6 million, 12.03% up from the prior year.
  • Depreciation & Amortization (CF) reached $8.1 million in Q4 2025 per AMPH's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $9.8 million in Q3 2024 and bottomed at $2.5 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $5.8 million, with a median of $5.3 million recorded in 2022.
  • The widest YoY moves for Depreciation & Amortization (CF): up 215.9% in 2024, down 24.84% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.6 million in 2021, then soared by 32.28% to $3.4 million in 2022, then soared by 180.86% to $9.7 million in 2023, then decreased by 24.84% to $7.3 million in 2024, then grew by 11.22% to $8.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $8.1 million in Q4 2025, $7.9 million in Q3 2025, and $8.3 million in Q2 2025.